DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 53.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,228 shares of the medical device company's stock after selling 40,004 shares during the period. Nisa Investment Advisors LLC's holdings in DexCom were worth $2,337,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Nia Impact Advisors LLC grew its position in shares of DexCom by 1.4% in the fourth quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock valued at $766,000 after purchasing an additional 140 shares in the last quarter. Level Four Advisory Services LLC boosted its stake in DexCom by 1.1% during the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock worth $1,026,000 after buying an additional 150 shares during the last quarter. Covestor Ltd grew its holdings in DexCom by 15.6% in the 4th quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock valued at $86,000 after buying an additional 150 shares in the last quarter. TD Private Client Wealth LLC increased its stake in shares of DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after acquiring an additional 167 shares during the last quarter. Finally, Personal CFO Solutions LLC increased its stake in shares of DexCom by 7.3% in the 1st quarter. Personal CFO Solutions LLC now owns 3,446 shares of the medical device company's stock worth $235,000 after acquiring an additional 234 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Analyst Ratings Changes

DXCM has been the subject of a number of analyst reports. Piper Sandler dropped their price objective on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Citigroup reissued a "buy" rating and issued a $102.00 price target (up previously from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Cfra Research upgraded shares of DexCom to a "hold" rating in a report on Friday, March 21st. Truist Financial began coverage on shares of DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price target on the stock. Finally, Canaccord Genuity Group increased their price objective on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $99.60.

DexCom Stock Down 0.0%

Shares of DXCM stock traded down $0.03 during trading on Thursday, reaching $84.10. The company's stock had a trading volume of 4,777,194 shares, compared to its average volume of 4,434,549. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $116.35. The stock's 50-day moving average price is $84.51 and its 200 day moving average price is $80.13. The company has a market capitalization of $32.98 billion, a price-to-earnings ratio of 62.76, a P/E/G ratio of 1.79 and a beta of 1.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The business's revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.32 EPS. On average, research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 500 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $41,400.00. Following the completion of the transaction, the executive vice president owned 95,102 shares in the company, valued at $7,874,445.60. The trade was a 0.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $83.13, for a total transaction of $228,607.50. Following the completion of the sale, the director directly owned 56,621 shares in the company, valued at approximately $4,706,903.73. This represents a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,190 shares of company stock worth $2,281,732 in the last quarter. Company insiders own 0.32% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.